DRKS00033663Not yet recruitingNot Applicable
Multi-centric Validation of the FAST4D Score in Emergency medical service STroke dEtection and Capability to predict large vessel occlusion eligible for endovascular Treatment - FAST4Detect
Justus-Liebig-Universität Gießen0 sites1,500 target enrollmentStarted: February 19, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 1,500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Patients who are referred to the emergency room with suspected stroke in one of the participating clinics. These patients receive a patient allocation code (PZC) from the emergency services, which they use to register electronically at the destination clinic. There are 3 codes for stroke, depending on the onset of symptoms. All patients with these codes are recorded: 421/422/423 (Apoplexy/TIA/Hemorrhage”)
- •In order to record patients who are not assigned as having a stroke but were diagnosed with a stroke during diagnostics, all patients with the corresponding discharge diagnosis are also recorded.
- •For the retrospective control group, the identification of patients is carried out in the same way by screening the patients who were suspected of having a stroke in the emergency room during this time and after the discharge diagnosis. The retrospective data collection will cover the year 2023.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.Actinic Keratosis on the Face or ScalpMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-004349-18-PLAlmirall, S.A.450
Active, not recruiting
Phase 1
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.EUCTR2021-004349-18-ESAlmirall, S.A.540
Recruiting
Phase 4
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or ScalpActinic Keratosis2024-514394-22-00Almirall S.A.418
Active, not recruiting
Phase 1
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.Actinic Keratosis on the Face or ScalpMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-004349-18-FRAlmirall, S.A.540
Active, not recruiting
Phase 1
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or ScalpActinic KeratosisCTIS2024-514394-22-00Almirall S.A.450